OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake

OPKO Health Inc. (NASDAQ:OPK) is one of the most promising penny stocks according to Wall Street analysts. On April 30, OPKO Health amended its agreement with Nicoya Therapeutics to grant OPKO a 15% equity interest in the firm, deepening its partnership to commercialize RAYALDEE in Greater China. While the equity stake modifies the royalty and transfer price schedule, the original milestone structure remains intact, keeping OPKO eligible for up to $115 million in potential development, regulatory, and sales-based payments.

Nicoya, a specialist in the Chinese nephrology market, is currently working to bring RAYALDEE to patients suffering from secondary hyperparathyroidism associated with chronic kidney disease. With the treatment already approved in Macau, both companies are targeting further regulatory approvals across China and its related territories in 2027 to address the needs of an estimated 20 million adults affected by stage 3 or 4 chronic kidney disease in the region.

OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake

Pixabay/Public domain

This collaboration uses OPKO Health Inc.’s (NASDAQ:OPK) integrated manufacturing and supply chain capabilities alongside Nicoya’s localized clinical and commercial expertise. Management noted that the expansion of this agreement aligns with the broader strategy to increase global patient access to RAYALDEE, representing a significant growth opportunity for both companies within the large and underserved Asian renal health market.

OPKO Health Inc. (NASDAQ:OPK) is a multinational biopharmaceutical and diagnostics company that discovers, develops, and commercializes pharmaceutical products and operates clinical laboratories. It focuses on treating serious diseases through products such as RAYALDEE and NGENLA, while also providing diagnostic services.

While we acknowledge the risk and potential of OPK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OPK and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1